Cardiol Therapeutics to Engage in Talks at B. Riley Securities Summit on Heart Disease Solutions

Cardiol Therapeutics to Engage in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

Cardiol Therapeutics Inc., traded on NASDAQ and TSX under the symbol CRDL, is set to showcase its latest innovations in the treatment of heart disease during a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision Summit. The event is scheduled to take place in Boston, Massachusetts, on July 16, 2026, at 12:20 PM EDT. This opportunity allows Cardiol to underline its commitment to advancing therapies that can significantly impact patients suffering from inflammatory heart conditions.

Addressing Heart Disease

Cardiol Therapeutics is a late-stage life sciences firm fundamentally focused on developing cutting-edge therapies aimed at alleviating inflammation and fibrosis linked to various heart diseases. Their flagship drug candidate, CardiolRx™, is designed to carefully modulate the inflammasome pathway—this is a key component of the body’s immune system that plays a crucial role in the development of conditions such as pericarditis, myocarditis, and heart failure.

The company’s clinical programs are designed to provide significant relief and restore quality of life for patients. One of the main highlights is the MAVERIC Program, which investigates CardiolRx™ specifically for recurrent pericarditis. This particular inflammatory condition is notorious for causing debilitating symptoms—including severe chest pain and shortness of breath—that can drastically impair a patient’s quality of life.

Clinical Trial Updates

The MAVERIC Program includes the completed Phase II MAvERIC-Pilot study and is currently advancing into the pivotal Phase III MAVERIC trial, aiming to finalize results and offer potentially life-changing treatments for affected patients. Recognizing its therapeutic potential, the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to CardiolRx™ for treatment modalities targeting recurrent pericarditis—demonstrating confidence in its efficacy and safety potential.

In addition to recurrent pericarditis, CardiolRx™ is also being evaluated in the ARCHER Program, which focuses on acute myocarditis. This condition is particularly concerning as it is a prevalent cause of severe heart failure among young adults and can lead to sudden cardiac deaths in individuals under thirty-five. The ARCHER program’s insights help solidify Cardiol’s commitment to addressing critical heart-related health crises among vulnerable populations.

Exploring New Innovations

Moreover, Cardiol Therapeutics is venturing into the development of CRD-38, which is an innovative subcutaneously administered drug formulation intended for treating various inflammatory heart diseases, including heart failure itself. Heart failure remains one of the leading causes of hospitalization and death across many developed regions, with the associated healthcare costs in the U.S. surpassing $30 billion annually. The advancement of CRD-38 highlights the company's mission to alter the landscape of heart disease treatment, potentially offering better options for patients and healthcare systems.

Upcoming Engagement

Participation at the B. Riley Securities summit provides Cardiol the platform to engage with investors, healthcare professionals, and clinical stakeholders about their ongoing and future projects. As Cardiol Therapeutics continues to advance its clinical programs, the insights shared during the Fireside Chat will offer a compelling look into the novel therapies that could reshape patient care in heart disease management.

Conclusion

In showcasing its innovations and clinical advancements at the B. Riley Securities Conference, Cardiol Therapeutics is poised to make a profound impact on the current trajectory of heart disease therapies. Ongoing clinical trials, regulatory insights, and an unwavering commitment to improving patient outcomes mark a promising future. Interested investors and stakeholders can track Cardiol's developments and access additional details through their official website at cardiolrx.com.